Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by 1998novlon Jul 14, 2016 4:30pm

110 Views

Post# 25053813

RE:RE:RE:RE:RE:Insider bought à lot on july 13 ☺

I would argue TH does have a $1B opportunity in the next 12 months - in fact Taimed has a market cap of $2.4B and they chose TH as a partner. How much do you think Gilead would value that partnership? Taimed's market cap may move towards $3B-$4B as FDA approval and the success of Ibalizumab take hold. The market is missing the TH story, but that's because nobody is paying attention! Early bird gets the worm, second mouse gets the cheese!

Bullboard Posts

Sirios Resource discovers visible gold in Quebec